Finance

Beta
Lists
SMMT:NASDAQ
Summit Therapeutics Inc
$15.42
+7.23%
(+1.04) 1D
$15.35
-0.45% (-0.070)
After hours
Closed: Jul 2, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SMMT...
Open
$14.55
High
$15.70
Low
$14.55
Mkt. cap
11.97B
Avg. vol.
6.46M
Volume
7.11M
52-wk high
$30.98
52-wk low
$12.55
EPS
-$1.60
Beta
-1.26
Shares outstanding
776.16M
No. of employees
265
Open
$14.55
High
$15.70
Low
$14.55
Mkt. cap
11.97B
Avg. vol.
6.46M
Volume
7.11M
52-wk high
$30.98
52-wk low
$12.55
EPS
-$1.60
Beta
-1.26
Shares outstanding
776.16M
No. of employees
265
News stories
From sources across the web
About Summit Therapeutics Inc
CEORobert Duggan | Maky Zanganeh
Employees265
Founded2003
Headquarters-
SectorBiotechnology
Websitesmmttx.com
Analyst ratings
Based on 13 analysts giving stock ratings to SMMT in the past 3 months
Buy
Buy
8
Hold
4
Sell
1
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for SMMT in the last 3 months.
Highest
Current $15.42
$45.00 (+191.83%)
Average
$29.25 (+89.69%)
Lowest
$9.80 (-36.45%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jeffrey Walch
Bernstein
Sell
Reiterated
$9.80
-36.4%
06/21/2026
Etzer Darout
Barclays
Hold
Maintained
$18.00
+16.7%
06/02/2026
Dara Azar
Stifel Nicolaus
Buy
Maintained
$45.00
+191.8%
06/01/2026
Bradley Canino
Guggenheim
Buy
Maintained
$40.00
+159.4%
06/01/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$40.00
+159.4%
05/31/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
$30.00
+94.6%
06/02/2026
Mitchell Kapoor
H.C. Wainwright
Hold
Reiterated
-
-
06/01/2026
Unknown Analyst
Bernstein
Sell
Initiated
$7.70
-50.1%
05/21/2026
Faisal Khurshid
Jefferies
Hold
Maintained
$17.00
+10.2%
05/21/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/06/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$34.00
+120.5%
05/01/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$41.00
+165.9%
05/01/2026
Kelsey Goodwin
Piper Sandler
Hold
Maintained
$16.00
+3.8%
05/01/2026
William Maughan
Clear Street
Buy
Maintained
$31.00
+101%
05/01/2026
Stephen Willey
Stifel Nicolaus
Buy
Initiated
$45.00
+191.8%
04/08/2026
Asthika Goonewardene
Truist Financial
Buy
Reiterated
$35.00
+127%
02/24/2026
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
208.02M
131.10M
147.29M
132.62M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
360.42M
103.12M
77.63M
62.59M
Operating expense
568.44M
234.21M
224.92M
195.21M
Total operating expenses
568.44M
234.21M
224.92M
195.21M
Operating income
-568.44M
-234.21M
-224.92M
-195.21M
Other non operating income
-53.00K
-
-
-
EBT including unusual items
-565.71M
-231.79M
-219.17M
-189.42M
EBT excluding unusual items
-565.71M
-231.79M
-219.17M
-189.42M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-565.71M
-231.79M
-219.17M
-189.42M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
2.98M
2.78M
5.88M
5.85M
Interest expense
-
-
-
-
Net interest expenses
2.98M
2.78M
5.88M
5.85M
Depreciation and amortization charges
-
-
-
-
EBITDA
-568.40M
-234.17M
-224.88M
-195.17M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer